Trastuzumab emtansine (Kadcyla®) is indicated as a single agent, for the adjuvant treatment of adults with HER2-positive, early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||20/01/2020|
|Rapid review completed||27/02/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical and cost effectiveness of trastuzumab emtansine compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||04/03/2020|
|Pre-submission consultation with Applicant||31/03/2020|
|Full submission received from Applicant||08/06/2020|
|Preliminary review sent to Applicant||29/10/2020|
|NCPE assessment re-commenced||30/11/2020|
|Factual accuracy sent to Applicant||11/02/2021|
|NCPE assessment re-commenced||17/02/2021|
|NCPE assessment completed||12/03/2021|
|NCPE assessment outcome||The NCPE recommends that trastuzumab emtansine (Kadcyla®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.